Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Par Pharma Begins Shipment Of Generic Provigil - Quick Facts

Par Pharmaceutical Companies, Inc. (PRX: Quote) on Friday said it began shipping all strengths of modafinil tablets, a generic version of Teva's Provigil brand. Par's initial shipments will comprise generically-labeled presentations of the Provigil product.

Par acquired the U.S. marketing rights to modafinil from Teva when Teva acquired Cephalon in 2011. According to IMS Health data, annual sales in the U.S. for Provigil are around $1.1 billion.

Modafinil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder.

Modafinil is contraindicated in patients with a known hypersensitivity to modafinil, armodafinil or its inactive ingredients.

Click here to receive FREE breaking news email alerts for Par Pharmaceutical Companies Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After initially showing a lack of direction, stocks have moved sharply lower over the course of the trading day on Thursday. The losses on the day are extending a recent downward trend by the markets, with the major averages falling to their lowest levels in over a month. After reporting a sharp jump in new orders for U.S. manufactured goods in the previous month, the Commerce Department released a report on Thursday showing that factory orders pulled back by a little more than expected in the month of August. First-time claims for U.S. unemployment benefits unexpectedly decreased in the week ended September 27th, according to a report released by the Labor Department on Thursday. The report said initial jobless claims fell to 287,000, a decrease of 8,000 from the previous week's revised level of 295,000.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.